Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Rosuvastatin 10 mg + fenofibrate 160 mg tablet
Therapeutic Category
Cardiology, Cardiovascular
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹169/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Rosumore F 10 Tablet is a fixed-dose combination medication that combines Rosuvastatin, a potent statin, and Fenofibrate, a fibrate class lipid-lowering agent. This synergistic combination is specifically designed to treat mixed dyslipidemia by targeting both elevated low-density lipoprotein cholesterol (LDL-C) and triglycerides, while improving high-density lipoprotein cholesterol (HDL-C) levels. Rosuvastatin works by inhibiting HMG-CoA reductase, reducing cholesterol synthesis in the liver, while Fenofibrate activates peroxisome proliferator-activated receptors (PPAR-alpha), enhancing the breakdown of triglyceride-rich particles. Rosumore F 10 is especially beneficial for patients with atherogenic dyslipidemia, often seen in metabolic syndrome, type 2 diabetes, or those who do not respond adequately to statin monotherapy. This tablet offers a comprehensive approach to lipid control and helps reduce the risk of atherosclerosis, coronary artery disease, stroke, and other cardiovascular events. It is usually administered once daily and is best taken under medical supervision with regular monitoring.
Common side effects may include headache, muscle pain, joint pain, nausea, abdominal discomfort, and elevated liver enzymes. Rare but serious side effects include myopathy, rhabdomyolysis, and pancreatitis, particularly when statins and fibrates are used together. Patients should be advised to report any signs of muscle tenderness, weakness, or dark-colored urine. Liver function and creatine kinase levels should be monitored periodically. Gastrointestinal disturbances or skin rash may also occur in some individuals.
Rosumore F 10 Tablet is indicated for the treatment of mixed dyslipidemia and severe hypertriglyceridemia in patients who require both LDL-C and triglyceride reduction. It is also prescribed to patients with cardiovascular risk factors, such as diabetes, hypertension, or a family history of heart disease, especially when monotherapy has proven insufficient.
Rosumore F 10 should be used under the guidance of a healthcare professional. It is contraindicated in patients with active liver disease, gallbladder disorders, severe kidney impairment, or known hypersensitivity to any of its components. The combination therapy increases the risk of muscle toxicity, particularly in elderly individuals or those with existing renal dysfunction. Alcohol should be avoided or minimized. This medication should not be used during pregnancy or breastfeeding. A lipid-lowering diet, regular physical activity, and routine laboratory monitoring are important to ensure safe and effective therapy.
Store Rosumore F 10 Tablet in a cool and dry place, preferably below 30°C. Protect the medication from moisture and direct sunlight. Keep out of reach of children. Do not use the medicine after its expiry date.
Composition : Aspirin 75mg + Rosuvastatin 10mg + Clopidogrel 75mg Tablet
Composition : Aspirin 75mg + Rosuvastatin 20mg + Clopidogrel 150mg Tablet
Composition : Aspirin 75 mg + Rosuvastatin 20 mg + Clopidogrel 75 mg capsule
Composition : Rosuvastatin 10 mg + Aspirin 75 mg tablet
Composition : Rosuvastatin 10mg + Clopidogrel 75mg Capsule
Composition : Rosuvastatin 10 mg + Ezetimibe 10 mg tablet
Composition : Rosuvastatin Calcium IP eq. to Rosuvastatin (as pellets) 20 mg. + Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg. Excipients q.s.
Composition : Rosuvastatin (5mg) tablet
Composition : Rosuvastatin 5mg + fenofibrate 160 mg tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Rosuvastatin 10 mg + Fenofibrate 160 mg Tablet is a lipid-lowering combination therapy used for the management of mixed dyslipidemia, high cholesterol, high triglyceride levels, and prevention of cardiovascular diseases such as heart attack and stroke. Rosuvastatin helps reduce LDL (bad cholesterol), while Fenofibrate lowers triglycerides and improves overall lipid profiles. This makes it a highly prescribed cardiovascular and metabolic care segment product, creating strong opportunities in the PCD pharma franchise market.
Medical distributors and wholesalers benefit from the consistent demand for comprehensive lipid management therapies. This combination is widely prescribed by cardiologists, physicians, and diabetologists for patients with multiple lipid abnormalities, ensuring regular repeat prescriptions, stable sales, and continuous market demand.
Yes, Cafoli Lifecare offers PCD pharma franchise opportunities in the cardiovascular and lipid-management segment, including Rosuvastatin 10 mg + Fenofibrate 160 mg Tablet. We provide monopoly rights, quality-assured manufacturing, promotional support, and reliable product availability to help franchise partners establish a strong presence in the chronic care market.
Wholesalers and stockists benefit from strong prescription-driven demand, long-term patient usage, and widespread acceptance among cardiac and metabolic care specialists. As lipid disorders often require continuous treatment, this combination offers steady product movement, repeat business opportunities, and sustainable profitability in pharmaceutical distribution.
Medical distributors, stockists, and pharma professionals interested in cardiovascular and lipid-lowering products can contact Cafoli Lifecare to discuss pricing, availability, monopoly franchise rights, and business opportunities. We provide complete support through marketing materials, dependable supply chains, and territory-based franchise assistance to help partners grow their business successfully.